Document ID: chunk:federal_register_of_legislation:F2024L01325:front:0:p2
Version: federal_register_of_legislation:F2024L01325
Segment Type: other
Provision Reference: 
Character Range: 3423–6875

overlap category, including myelodysplastic/myeloproliferative neoplasm with neutrophilia; and myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis; and myelodysplastic/myeloproliferative neoplasm not otherwise specified.
Note: Myelodysplastic neoplasms are also called myelodysplastic syndromes and myelodysplastic disorders
 1.           While myelodysplastic neoplasm (syndrome) attracts ICD‑10‑AM codes D46 and C94.6, in applying this Statement of Principles the meaning of myelodysplastic neoplasm (syndrome) is that given in subsection (2).
 2.           For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.
Death from myelodysplastic neoplasm (syndrome)
 1.           For the purposes of this Statement of Principles, myelodysplastic neoplasm (syndrome), in relation to a person, includes death from a terminal event or condition that was contributed to by the person's myelodysplastic neoplasm (syndrome).
Note: terminal event is defined in the Schedule 1 – Dictionary.
 1.                Basis for determining the factors
The Repatriation Medical Authority is of the view that there is sound medical-scientific evidence that indicates that myelodysplastic neoplasm (syndrome) and death from myelodysplastic neoplasm (syndrome) can be related to relevant service rendered by veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the MRCA.
Note: MRCA, relevant service and VEA are defined in the Schedule 1 – Dictionary.
 1.                Factors that must exist
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting myelodysplastic neoplasm (syndrome) or death from myelodysplastic neoplasm (syndrome) with the circumstances of a person's relevant service:
 1.           smoking at least 10 pack-years of cigarettes, or the equivalent thereof in other tobacco products, before clinical onset, and:
         1.           smoking commenced at least 5 years before clinical onset; and
         2.           where smoking has ceased, clinical onset has occurred within 15  years of cessation;
Note: one pack-year is defined in the Schedule 1 – Dictionary.
 1.           being treated with one of the following drugs:
         1.           a topoisomerase II inhibitor, including etoposide, and doxorubicin; or
         2.           an alkylating agent including cyclophosphamide, chlorambucil, mechlorethamine, melphalan, nitrosoureas, cisplatin, carboplatin; or
         3.            azathioprine;
         4.           5-fluorouracil;
         5.           taxanes including paclitaxel, and docetaxel;
         6.            granulocyte colony stimulating factor;
before clinical onset, where treatment commenced at least 6 months before clinical onset, and where the treatment has ceased, within 20 years of cessation;
 1.           having received a cumulative equivalent dose of at least 0.01 sievert of ionising radiation to the bone marrow at least 1 year before clinical onset;
Note: cumulative equivalent dose is defined in the